Paydirt
OL
Insider

OrbiMed Genesis GP LLC

Director

OrbiMed Genesis GP LLC (Director) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Edgewise Therapeutics, Inc. (EWTX). Across 2 priced purchase filings, the average 21-session return was +5.7% from execution and +4.1% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of EWTX (496,771 sh across 2 lots, as filed), executed Apr 3 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+5.7%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+4.1%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$12.0M
shares × price, as filed
Last traded
Apr 3 2025
Filed Apr 4 2025

Median ADV $64.2M across their filed names

Open performance
Volume by month
$10.0M$5.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Feb 2025 · buys $2.0MApr 2025 · buys $10.0M
Buys $12.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing Not on file 1 filing

Sector per market data · by filing · past 24 months

Most traded names
EWTX Edgewise Therapeutics, Inc. EWTX · 1 buy · 0 sells 1 filing MBX MBX MBX · 1 buy · 0 sells 1 filing
Recent filings
EWTXPURCHASE Edgewise Therapeutics, Inc. View filing → $10.0M
496,771 sh across 2 lots
Exec Apr 3 2025
Filed Apr 4 2025 · 5:30 PM ET
MBXPURCHASE MBX Biosciences, Inc. View filing → $2.0M
190,672 sh across 4 lots
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET